Overview
Bionova Scientific is a biologics contract development and manufacturing organization (CDMO) specializing in monoclonal antibodies and therapeutic proteins using mammalian cell culture processes. The company provides end-to-end services from discovery through cGMP commercial manufacturing, with capabilities in transient and stable protein production, process development, and plasmid DNA manufacturing. Operating state-of-the-art facilities in the San Francisco Bay Area and Houston, Texas, Bionova serves pharmaceutical companies developing complex next-generation antibody-based drugs and advanced therapies.
Frequently asked questions
- What protein production methods does Bionova offer?
- Bionova offers both transient production in CHO and HEK 293 cells (up to 20L shake flasks) and stable pool or clone production (up to 50L bioreactor scale). Production scales range from bench-scale shake flasks to 50L in their pilot facility, with capability to deliver dozens of grams for animal studies or clinical requirements.
- What regulatory and manufacturing capabilities does Bionova provide?
- Bionova operates a state-of-the-art GMP manufacturing facility that opened in 2021 and is currently producing clinical supply for clients. The company provides cGMP commercial supply services with platform or customized downstream processes, supported by electronic records access and daily readouts on cell culture and purification.
- What new services has Bionova recently launched?
- In 2025, Bionova expanded into advanced therapies by establishing a dedicated plasmid DNA (pDNA) development and manufacturing facility in The Woodlands, Texas. This facility began process development services in the first quarter of 2025 and GMP manufacturing later in 2025, enabling Bionova to serve cell and gene therapy markets.
- What is Bionova's parent company and geographic presence?
- Bionova Scientific is a U.S. subsidiary of Asahi Kasei Medical, part of the Asahi Kasei Group. The company operates facilities in the San Francisco Bay Area and Houston, Texas, positioning it as a flexible partner for advanced therapy production across multiple therapeutic modalities.